Connect with us

Cannabis

First harvest of German medical cannabis is likely to be delayed again

As a consequence of the coronavirus pandemic, the first harvest of German medical cannabis will probably be delayed again by several months. In these conditions, medical cannabis patients in the country will have to continue to rely on imports. Demecan clearly stated that it will not be able to harvest medical cannabis for commercial distribution this year.

Published

on

This picture show a hemp field.

As with the construction of Berlin’s major airport BER, it seems quite problematic to put the plans into practice with regard to the professional care of medical cannabis patients. 

After the distribution of the cultivation licenses was already delayed several times and the lucky winners of the distributed lots started the race for the cultivation in Germany with a late start, now probably the circumstances caused by the Coronavirus pandemic have led to the fact that only next year high-quality medical cannabis can be harvested in this country. The first harvest of German medical cannabis will probably be delayed again by several months.

Find out why the first medical cannabis harvest in Germany will be delayed and read the most important cannabis news with the Born2Invest mobile app. 

German patients might still need to rely on medical cannabis from abroad

As reported on Marijuana Business Daily, it does not seem possible that the German producers of medical cannabis will be able to meet the planned harvest date in November. After receiving a small inquiry from Dr. Wieland Schinnenburg, Michael Theurer and Jens Beeck (FDP) to the German government, they received the answer that it cannot be excluded that due to the COVID-19 pandemic, a delay in the delivery of medical cannabis this year could occur. “It cannot be ruled out that the ongoing effects of the COVID-19 pandemic in many sectors of the economy could have a delayed impact on the start of deliveries in 2020,” mjbizdaily.com said. 

This would mean that German cannabis patients would continue to depend on the import of sufficient medical cannabis from the federal government in the coming months, which has not always worked ideally in the past. Based on the available information, the mentioned website inquired with the three large companies that received the contracts for cultivation in Germany about their level of knowledge and was able to find out that the sand is in the gear. 

SEE ALSO  These travel destinations live up to the hype

What do the three licensed cannabis companies say about a possible delay

The German company Demecan and the Canadian company Aphria confirmed that a harvest in early 2021 was part of the new plan. Canadian-based Aurora Cannabis said through the flower that it looks forward to starting production once certain steps have been taken that would be challenging due to the current pandemic. However, the company is committed to the tender specifications, Philip Schetter, the managing director of Aurora Germany, is said to have added when asked. 

They are looking forward to starting and ramping up production as soon as all necessary steps for production preparation and regulatory approvals have been completed. Aphria, on the other hand, admitted that a slight delay in the completion of their facility is to be expected. Assuming that all BfArM and local authority inspections are on schedule, the company now expects a first crop in the first quarter of 2021. Meanwhile, Demecan clearly stated that it will not be able to harvest medical cannabis for commercial distribution this year. All three companies attributed the probably inevitable delays to the ongoing COVID 19 pandemic.

The German Federal Office for Drugs and Medical Devices is therefore completely uninvolved in these circumstances – just as it is in the import of the now more urgently needed medical cannabis buds from the foreign countries that earn well from it. 

__

(Featured image by TinaKru via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in HanfJournal, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Anthony Donaghue writes about science and technology. Keeping abreast of the latest tech developments in various sectors, he has a keen interest on startups, especially inside and outside of Silicon Valley. From time to time, he also covers agritech and biotech, as well as consumer electronics, IT, AI, and fintech, among others. He has also written about IPOs, cannabis, and investing.